Swiss doctors are demanding improved access to vaccines following repeated shortfalls, not least during the coronavirus pandemic. Vaccine production has dwindled in Switzerland, leaving the country reliant on imports to meet its needs.
“Patients are calling us and we then have to tell them that there is nothing left,” he said.
The Covid-19 pandemic is not the only instance of the supply of vaccines falling short of demand, he added. National campaigns to fight against measles, mumps, rubella or the tick transmitted TBE have run out of vaccines before the end of the campaign.
The main problem is finding secure supplies of vaccines, which are made in countries such as India and China but hardly any more in Switzerland. Vaccine production tailed off at Berna Biotech after it was taken over by Dutch biotechnology company Crucell and later Johnson & Johnson. Novartis sold most of its vaccine unit to GlaxoSmithKline in 2015.
Switzerland applies different regulatory standards for vaccines than most of Europe, complained Quinto. In addition, it does not have the bargaining power of European purchasing chains. This makes it harder to get enough stocks of vaccines.
“The government has to sit at a table with us to find solutions,” demands Quinto.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Uri voters clear path for hotel and marina complex in central Switzerland
This content was published on
Voters in canton Uri in central Switzerland have rejected a Green Party initiative aimed at regulating the development of the lakeside site in Isleten.
Valais voters reject plan to achieve carbon neutrality by 2040
This content was published on
Voters in canton Valais in southern Switzerland have turned down a proposal for the region to achieve carbon neutrality by 2040.
Swiss central banker wants to boost equity to head off risks
This content was published on
Equity levels at the Swiss National Bank (SNB) are much too low for the risks its large balance sheet poses, according to Martin Schlegel.
Beer sales in Switzerland watered down by bad weather
This content was published on
The past brewing year fell through in Switzerland, partly due to the bad weather. Beer sales shrank again. For the first time, per capita consumption fell below the 50 liter mark.
This content was published on
As money is poured into the search for a silver bullet to Covid-19, some experts warn that the pandemic could also worsen the antibiotics crisis.
Novartis steps up coronavirus fight as part of new collaboration
This content was published on
Several big pharmaceutical companies have joined forces with the Bill & Melinda Gates Foundation in response to the coronavirus pandemic.
Who decides who gets access to the silver bullet to Covid-19?
This content was published on
Our regular analysis of what the biggest global companies in Switzerland are up to. This week: multinationals confront national interests.
Intensive care beds could run out in a week, study predicts
This content was published on
Switzerland will run out of intensive care beds on April 2 owing to the progression of the coronavirus pandemic, according to a study by ETH Zurich.
This content was published on
The government has banned gatherings of more than five people, warning that CHF100 fines will be handed out to violators. Daniel Koch, head of communicable diseases at the Federal Office of Public Health, said it would take several days for the new restrictions to slow infection rates. “I am confident that we will probably see…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.